In lung cancer, the high heterogeneity of expression in stroma and tumor cells reflects the controversial clinical value of SPARC and gives different results in cohorts of patients with different disease stages and treatments [9,10] By contrast, SPARC has a high binding affinity to albumin and its stromal expression of this protein in lung carcinoma might be considered a potential predictive biomarker in drawing albumin-bound paclitaxel to tumor cells and enhancing the ability of tumor destruction [11,12]. Here, SPARC is linked to lung carcinoma.